Cerebrolysin is a nootropic drug that may improve cognitive function and memory. A number of countries use this drug to treat dementia, stroke, and brain injury. Read more to learn about the effects and uses of this drug and its potential side effects.
What Is Cerebrolysin?
Cerebrolysin is purported to be a nootropic, a “smart drug” that can improve cognitive function. It is a mixture of amino acids and proteins derived from pig brains, including:
- Brain-derived neurotrophic factor (BDNF) [R]
- Glial cell line-derived neurotrophic factor (GDNF) [R]
- Nerve growth factor (NGF) [R]
- Ciliary neurotrophic factor (CNTF) [R]
These proteins are also found naturally in the human brain, where they play an important role in brain cell development and repair [R].
Cerebrolysin is not approved for medical use in the United States. However, this drug is sometimes used in a number of European and Asian countries for the treatment of stroke, traumatic brain injury, and dementia [R, R].
How Does Cerebrolysin Work?
According to research, Cerebrolysin may work by:
- Protecting brain cells and preventing their death due to harmful conditions [R, R].
- Promoting the growth of new brain cells [R].
- Improving brain cell communication, which enhances learning capacity [R, R, R].
- Increasing brain energy (by increasing glucose uptake by brain cells) and protein production in cells [R, R].
- Decreasing brain levels of beta-amyloid deposits, which are linked to Alzheimer’s disease [R].
- Lowering inflammation in the brain [R].
Uses of Cerebrolysin
Cerebrolysin is not approved for medical treatment in the United States. Other countries sometimes use this drug for the treatment of several conditions, which are described below. Cerebrolysin should always be taken under the guidance of a doctor.
For example, one randomized placebo-controlled multicenter clinical trial of 208 patients examined the effects of taking Cerebrolysin within 72 hours of a stroke and for 21 days after. Researchers found that those on Cerebrolysin performed better on tests measuring cognition and motor function [R].
However, there is conflicting evidence as well. A systematic review of 6 clinical trials including 1,501 patients found that Cerebrolysin did not have any clinical benefit over placebo. In addition, this drug was associated with a higher number of side effects. Another meta-analysis of 7 studies also found no benefit with Cerebrolysin [R, R].
2) Traumatic Brain Injury
A systematic review of 5 clinical trials including 5,685 patients suggests that Cerebrolysin may protect against cognitive and motor deficits associated with brain injury [R].
In a randomized placebo-controlled trial of 32 patients, Cerebrolysin also improved long-term memory.
Another randomized placebo-controlled trial of 158 infants found that Cerebrolysin may prevent speech deficits and improve social interaction in newborns with severe brain injury [R].
However, in many of these studies, Cerebrolysin did not reduce the risk of death associated with traumatic brain injury [R].
Several clinical trials have studied the potential benefits of Cerebrolysin on vascular dementia, a form of dementia caused by impaired blood flow to the brain. These studies suggest that Cerebrolysin may improve cognition, memory, and general function [R, R].
However, a systematic review of 6 clinical trials including 597 patients concluded that the supporting evidence is weak. Researchers suggest there may be a high risk of bias and the effect of Cerebrolysin may be too small to be clinically meaningful [R].
4) Alzheimer’s Disease
Another review of 15 clinical trials including 2,446 subjects suggests that high doses of Cerebrolysin may reduce psychological symptoms and slow disease progression in patients with Alzheimer’s [R].
The following purported benefits of Cerebrolysin are only supported by limited, low-quality clinical studies. There is insufficient evidence to support the use of Cerebrolysin for any of the uses listed below.
Cerebrolysin should always be taken under the guidance of a doctor. It should never be used as a replacement for approved medical therapies.
According to a study of 109 schizophrenic patients, Cerebrolysin (added to risperidone) may improve cognitive function and memory [R].
Another study of 54 older adults with memory loss found that a derivative of Cerebrolysin, N-PEP-12, improved memory [R].
In a small study of 6 healthy elderly subjects, a single dose of Cerebrolysin improved memory and attention [R].
A study of 20 patients with treatment-resistant depression found that Cerebrolysin, in combination with conventional antidepressants, may be more effective for improving symptoms than antidepressants alone [R].
A different study of 40 patients with depression found that the addition of Cerebrolysin to venlafaxine (an antidepressant) may improve response to antidepressant therapy and reduce side effects [R].
In a study of 19 children with childhood autism and 8 with Asperger’s syndrome, Cerebrolysin therapy improved cognitive function in all Asperger’s and in 89% of autistic patients [R].
In another study of 43 children with autism, 27 children (62.8%) showed signs of improvement after receiving the drug [R].
In a study of 60 children with ADHD, Cerebrolysin improved symptoms in 70 to 86% of subjects [R].
According to a study of 50 children with cerebral palsy, Cerebrolysin may improve motor function when added to rehabilitation therapy [R].
Rett syndrome is a rare genetic brain disorder characterized by impaired speech, coordination, and movement.
A pilot study of 9 girls with RETT syndrome found that Cerebrolysin may improve behavior, attention, physical skills, and nonverbal social communication. It also may restore high-level brain functions, as measured by EEG [R].
In a study of 20 patients with type 2 diabetes, Cerebrolysin relieved pain associated with diabetic neuropathy (nerve damage caused by diabetes). A 10-day therapy led to improvements that lasted at least 6 weeks [R].
No clinical evidence supports the use of Cerebrolysin for any of the conditions listed in this section. Below is a summary of the existing animal and cell-based research, which should guide further investigational efforts. However, the studies listed below should not be interpreted as supportive of any health benefit.
Cerebrolysin nanospheres slowed disease progression in a mouse model of Parkinson’s [R].
A study of rats with Parkinson’s disease suggests that Cerebrolysin may promote the survival of brain cells and improve motor symptoms [R].
Safety of Cerebrolysin
- Burning sensation
- Weight loss
- Flu-like symptoms
- Vomiting with heart palpitations (rarely)
- Injection site reactions (irritation, itchiness)
There is some evidence that Cerebrolysin may increase the risk of seizures. Those at risk for seizures, including epileptic patients, should avoid this drug [R].
If you take Cerebrolysin, let your doctor know as there may be unexpected and potentially dangerous interactions with your other medications or health conditions. The drug interactions of Cerebrolysin are not well researched and there may be more potential interactions beyond the ones discussed here.
Cerebrolysin is available as a solution, which can be administered through IV injection, IM injection, or IV infusion. Doses should be administered by a health professional [R].
Doses of Cerebrolysin can range from 10 to 50 ml per day, depending on the condition and the age of the patient. Each ml contains 215.2 mg of Cerebrolysin [R].
Carriers of a gene variant that increases the risk of Alzheimer’s disease, APOE-ε4 (rs7412-C, rs429358-C), may have a decreased response to Cerebrolysin. In one study, Alzheimer’s patients without this variant were three times more likely to respond to treatment [R].
However, in another study, Cerebrolysin was more effective in raising levels of BDNF, a protein that enhances brain cell growth and survival, in APOE-ε4 carriers [R].
P21 (Peptide 021) is a derivative of cerebrolysin. Mouse studies suggest that it may also enhance learning and short-term and spatial memory [R].
According to a study in aged rats, P21 may increase BDNF and neurogenesis [R].
Cortexin, a protein-based nootropic drug, is also similar to cerebrolysin. However, it differs in composition (more proteins). A study comparing the behavioral effects of cortexin and cerebrolysin in rats revealed that cortexin had a more pronounced psychological effect (e.g., reduced anxiety) [R].